Malaria Research Advances on Multiple Fronts as Drug Resistance Grows and New Vaccine Technologies Emerge

Malaria research is advancing rapidly as the deadly Plasmodium falciparum parasite develops increasingly complex, localized drug resistance. A genetic study of 605 Ethiopian samples revealed widespread resistance markers to both retired drugs like chloroquine and current frontline therapies, with 93% showing reduced sensitivity to lumefantrine. Concurrently, scientists have designed a novel multi-region peptide vaccine add-on that overcomes immunogenic gaps in current WHO-approved vaccines, successfully blocking parasites from reaching the liver in animal models. These developments coincide with the FDA's landmark approval of Moderna's mFlusiva, the first mRNA flu shot, which highlights the growing potential of mRNA platforms to combat fast-mutating pathogens like malaria.

Plasmodium falciparum drug resistance

• ▪A genetic analysis of Plasmodium falciparum in Ethiopia revealed that the malaria parasite is stockpiling adaptations linked to resistance against multiple drug treatments.
• ▪Artemisinin partial resistance in Plasmodium falciparum was first identified in Southeast Asia over 15 years ago and has since been reported in multiple African locations.
• ▪The malaria parasite Plasmodium falciparum has developed resistance to almost all antimalarial treatments developed over the last 70 years, including artemisinin.

Ethiopian parasite genetic analysis

• ▪Genetic resistance patterns to chloroquine were found in 61.2 percent of 492 successfully classified Plasmodium falciparum samples from Ethiopia, despite the drug being withdrawn decades ago.
• ▪In the Ethiopian genetic study, 93 percent of 483 classified Plasmodium falciparum samples carried a genetic pattern associated with reduced sensitivity to lumefantrine.
• ▪Researchers sequenced drug-resistance genes from 605 Plasmodium falciparum samples collected across 15 Ethiopian districts between 2019 and 2023.

PfCSP vaccine immunogenicity gaps

• ▪The RTS,S and R21 malaria vaccines only present the major repeat region of the PfCSP protein to the immune system, failing to target the minor repeat and junction regions.
• ▪A study from the Batista Lab found that the major repeat region of the PfCSP protein immunologically drowns out the minor repeat and junction regions when the full protein is administered.
• ▪The World Health Organization currently recommends two malaria vaccines, RTS,S and R21, but neither works as effectively or as long as public health officials desire.

Multi-region peptide vaccine approach

• ▪Researchers at the Batista Lab developed a combination vaccine approach using the R21-style protein alongside two short peptides targeting the minor repeat and junction regions of PfCSP.
• ▪In mouse models, the multi-region peptide vaccine combination was the only approach tested that significantly reduced the number of malaria parasites reaching the liver.

Moderna mFlusiva flu approval

• ▪The U.S. Food and Drug Administration approved Moderna's mFlusiva, the country's first mRNA-based influenza vaccine, on August 5, 2026.
• ▪Moderna's mFlusiva vaccine received traditional FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older.